Cyfuse Biomedical K.K.
4892株式会社サイフューズ
Latest half-year results
First half · fiscal year to 2026-12 · filed 2026-08-14For the first half of the fiscal year to 2026-12: Revenue ¥0.1 billion (+254.6% YoY), Ordinary income ¥-0.4 billion, Net income ¥-0.4 billion.
| This period | Year on year | |
|---|---|---|
| Revenue | ¥104m | +254.6% |
| Ordinary profit | −¥433m | — |
| Net profit to owners | −¥435m | — |
From the securities report on EDINET, which states no forecast. History via /v1/companies/4892/earnings-releases.
Financials
Japan GAAP · non-consolidated · fiscal year to 2025-12-31- Revenue
- ¥231m
- Net income
- −¥764m
- ROE
- —
- Equity ratio
- 62.3%
- Dividend / share
- —
- Employees
- 23
| Fiscal year | Revenue | Net income | Total assets | Net assets | ROE | EPS | Operating CF |
|---|---|---|---|---|---|---|---|
| 2025-12-31 | ¥231m | −¥764m | ¥4,266m | ¥2,758m | — | ¥-86.78 | −¥535m |
| 2024-12-31 | ¥54m | −¥872m | ¥3,518m | ¥2,542m | — | ¥-108.34 | −¥761m |
| 2023-12-31 | ¥61m | −¥589m | ¥4,215m | ¥3,203m | — | ¥-75.42 | −¥562m |
| 2022-12-31 | ¥374m | −¥474m | ¥4,815m | ¥3,770m | — | ¥-177.67 | −¥404m |
| 2021-12-31 | ¥708m | ¥143m | ¥2,646m | ¥1,900m | 8.3% | ¥285.53 | ¥162m |
Indicators
Computed by us from filings · fiscal year to 2025-12-31| Metric | Value | Percentile among listed companies |
|---|---|---|
| ROE, % | — | — |
| Ordinary margin | -3.2957 | 0.7 |
| Equity ratio, % | 62.3 | 62 |
| Revenue growth | 3.2427 | 99.8 |
| Net income growth | 0.1243 | 48.9 |
| Operating cash flow / assets | -0.1254 | 4 |
Results wording balance: +1.00. Proprietary text method; it describes the wording only and does not interpret context.
Interest example: if all ¥1.3bn of reported debt repriced by 50 basis points, a year's interest would rise by ¥7m. Our arithmetic only, not a forecast: fixed-rate debt and hedges are ignored.
Via /v1/companies/4892/indicators. Descriptive figures, not a rating and not investment advice.
From other filings
As the company states themSegments, votes and tender offers
Stated in EDINET filings/v1/companies/4892/votingOwnership changes
All companies →- 2026-05-12
SBI Ventures Two Co., Ltd. reduced holdings in Cyfuse Biomedical K.K. (4892) to 7.71% from 9.92%.
- 2026-04-28
individual filer reduced holdings in Cyfuse Biomedical K.K. (4892) to 7.31% from 8.33%.
- 2026-04-27
SBI Ventures Two Co., Ltd. reduced holdings in Cyfuse Biomedical K.K. (4892) to 9.92% from 10.64%.
- 2026-04-27
Holdings of SBI Ventures Two Co., Ltd. in Cyfuse Biomedical K.K. (4892) moved below 10% (10.64% -> 9.92%).
- 2026-01-23
SBI Ventures Two Co., Ltd. reduced holdings in Cyfuse Biomedical K.K. (4892) to 10.64% from 11.67%.
- 2025-10-01
SBI Ventures Two Co., Ltd. reduced holdings in Cyfuse Biomedical K.K. (4892) to 11.67% from 12.29%.
- 2025-09-26
SBI Ventures Two Co., Ltd. reduced holdings in Cyfuse Biomedical K.K. (4892) to 12.29% from 13.27%.
- 2025-09-12
SBI Ventures Two Co., Ltd. reduced holdings in Cyfuse Biomedical K.K. (4892) to 13.27% from 14.26%.
- 2025-09-02
SBI Ventures Two Co., Ltd. reduced holdings in Cyfuse Biomedical K.K. (4892) to 14.26% from 15.38%.
- 2025-08-22
SBI Ventures Two Co., Ltd. reduced holdings in Cyfuse Biomedical K.K. (4892) to 15.38% from 17.41%.
Trades by 5% holders
From the 60-day trade tables in 5% reports| Holder | Period | Net shares | Net % of shares | Avg. filed price | Range |
|---|---|---|---|---|---|
| 株式会社SBI証券 | 2023-03-17 – 2026-04-30 | +33,500 | +0.38pt | ¥902.88 | ¥449–999 |
| individual filer | 2022-12-26 – 2026-04-24 | +437,500 | +5.56pt | ¥178.96 | ¥100–250 |
| individual filer | 2023-12-15 – 2025-04-25 | +185,500 | +2.30pt | ¥220 | ¥220–220 |
| SBI Ventures Two株式会社 | 2025-03-05 – 2025-03-06 | -18,700 | −0.23pt | — | — |
| 富士フイルム株式会社 | 2023-06-29 – 2023-06-29 | -300,300 | −3.84pt | — | — |
| 株式会社SBI証券 | 2022-12-02 – 2023-05-02 | +229,300 | +3.14pt | — | — |
| SBIインベストメント株式会社 | 2023-04-04 – 2023-04-10 | -200,000 | −2.56pt | — | — |
Net shares and the average are our calculations. Prices are filed prices as stated by the filer, mostly for off-market trades; they are not market prices. Stock lending, custody transfers and option exercises are excluded from net shares. Every row via /v1/companies/4892/trades.
5% filings
Large shareholding reports on 4892| Filed | Filer | Stake | Change | Stated purpose |
|---|---|---|---|---|
| 2026-05-12 | SBI Ventures Two Co., Ltd. | 7.71% | −2.21pt | pure investment |
| 2026-04-28 | individual filer | 7.31% | −1.02pt | — |
| 2026-04-27 | SBI Ventures Two Co., Ltd. | 9.92% | −0.72pt | pure investment |
| 2026-01-23 | SBI Ventures Two Co., Ltd. | 10.64% | −1.03pt | pure investment |
| 2025-10-01 | SBI Ventures Two Co., Ltd. | 11.67% | −0.62pt | pure investment |
| 2025-09-26 | SBI Ventures Two Co., Ltd. | 12.29% | −0.98pt | pure investment |
| 2025-09-12 | SBI Ventures Two Co., Ltd. | 13.27% | −0.99pt | pure investment |
| 2025-09-02 | SBI Ventures Two Co., Ltd. | 14.26% | −1.12pt | pure investment |
| 2025-08-22 | SBI Ventures Two Co., Ltd. | 15.38% | −2.03pt | pure investment |
| 2025-08-18 | SBI Ventures Two Co., Ltd. | 17.41% | −1.16pt | pure investment |
Cross-shareholdings
From the annual report's status of shareholdings- Listed strategic holdings
- — issues
- Book value
- —
- Sold in the year
- — — issues
- Bought in the year
- — — issues
- Mutual, both reports
- 0
- Held by listed cos.
- 3
Held by: TAIYO HOLDINGS CO., LTD. 4626, ZACROS Corporation 7917, SHIBUYA CORPORATION 6340
Purposes, all holdings and mutual flags via /v1/companies/4892/cross-holdings. Share changes include stock splits.
Major shareholders
As of fiscal year end 2025-12-31| Shareholder | Shares | Ratio |
|---|---|---|
| 株式会社SBI証券 | 535,100 | 5.56% |
| individual holder | 511,200 | 5.31% |
| SBI Ventures Two株式会社 | 462,700 | 4.81% |
| individual holder | 383,900 | 3.99% |
| individual holder | 313,000 | 3.25% |
| 楽天証券株式会社共有口 | 244,600 | 2.54% |
| 株式会社SBI新生銀行 | 223,000 | 2.32% |
| individual holder | 189,900 | 1.97% |
| PHC株式会社 | 185,100 | 1.92% |
| 福岡地所株式会社 | 175,200 | 1.82% |
Get this as JSON
GET /v1/companies/4892
GET /v1/companies/4892/financials
GET /v1/companies/4892/details
GET /v1/companies/4892/segments
GET /v1/companies/4892/voting
GET /v1/companies/4892/tender-offers
GET /v1/companies/4892/indicators
GET /v1/companies/4892/earnings-releases
GET /v1/events?ticker=4892
GET /v1/companies/4892/trades
GET /v1/companies/4892/cross-holdings
GET /v1/companies/4892/brief